In Australian BRCA Patent Challenge, Plaintiffs Not Satisfied With Myriad's IP Gift
November 03, 2010
In Australian BRCA Patent Challenge, Plaintiffs Not Satisfied With Myriad's IP Gift
Plaintiffs challenging one of Myriad's BRCA patents in the Australian federal court have applied to extend the scope of the case to include additional BRCA patents held by the company.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- US DoJ Argues Against Patenting Isolated Genes, But USPTO Will Maintain Status Quo
November 3, 2010 / Pharmacogenomics Reporter - Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010 / Pharmacogenomics Reporter - Myriad Assures Investors of Strong Patent Position Despite ACLU Anti-Gene Patenting Lawsuit
March 10, 2010 / Pharmacogenomics Reporter - 'Isolated DNA' Definition May Be Biggest Barrier to Summary Judgment at Anti-Gene Patenting Hearing
February 3, 2010 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter